Emmanuel Appiadu
Psychiatric/Mental Health · Yulee, FLNPI 1770913444
Payments from drug & device makers
Across 368 payments — averaging $26.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$809
- Teva Pharmaceuticals USA, Inc.$789
- Neurocrine Biosciences, Inc.$743
- plus $3K from 17 others
What the payments were for
- Food & beverage$9,47798%
- Education$1582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 44 | $1,624 |
| Otsuka America Pharmaceutical, Inc. | 50 | $1,580 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $1,010 |
| Alkermes, Inc. | 25 | $809 |
| Teva Pharmaceuticals USA, Inc. | 49 | $789 |
| Neurocrine Biosciences, Inc. | 30 | $743 |
| AbbVie | 31 | $601 |
| Supernus Pharmaceuticals, Inc. | 29 | $582 |
| Axsome Therapeutics, Inc. | 10 | $451 |
| Vanda Pharmaceuticals Inc. | 16 | $427 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $248 |
| Indivior Inc. | 7 | $146 |
| Eisai Inc. | 3 | $129 |
| E.r. Squibb & Sons, L.L.C. | 5 | $121 |
| Avanir Pharmaceuticals, Inc. | 1 | $111 |
| Sunovion Pharmaceuticals Inc. | 6 | $85 |
| Pear Therapeutics (US), Inc. | 1 | $58 |
| Lundbeck LLC | 2 | $32 |
| Corium, LLC | 2 | $24 |
| Noven Therapeutics, LLC | 1 | $22 |
| Tris Pharma Inc | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$894
- ABILIFY MAINTENA$491
- ARISTADA$450
- SPRAVATO$402
- REXULTI$350
- CAPLYTA$350
- ABILIFY ASIMTUFII$262
- INVEGA SUSTENNA$252
- INVEGA TRINZA$252
- INGREZZA$246
- Auvelity$231
- INVEGA$120
- VRAYLAR$118
- Fanapt$115
- ARISTADA INITIO$112
- NUEDEXTA$111
How this compares
$9,636 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 37 | $315,804 |
| AustedoDeutetrabenazine | 16 | $90,675 |
| Abilify MaintenaAripiprazole | 25 | $74,002 |
| Abilify AsimtufiiAripiprazole | 11 | $61,652 |
| RexultiBrexpiprazole | 19 | $31,378 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $25,419 |
| TrintellixVortioxetine Hydrobromide | 40 | $22,682 |
| FanaptIloperidone | 12 | $19,077 |
| CaplytaLumateperone Tosylate | 11 | $17,371 |
| VraylarCariprazine Hcl | 12 | $16,693 |
| LamictalLamotrigine | 24 | $11,454 |
| Methylphenidate ErMethylphenidate Hcl | 15 | $7,321 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,076 |
| Hydroxyzine Hcl | 93 | $2,822 |
| Clozapine | 14 | $2,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $743 | $315,80437 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti | $1,580 | $167,03355 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $789 | $90,67516 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $248 | $27,75853 claims |
| Alkermes, Inc.Lybalvi | $809 | $25,41916 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $427 | $19,07712 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,010 | $17,37111 claims |
| AbbVieVraylar | $601 | $16,69312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Yulee
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.